Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs TransMedics Group Inc — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while TransMedics Group Inc trades at $79.01 (market cap $2.81B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is more actively traded (962,415 versus 5,448,712). Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and TransMedics Group Inc for 24 Days on average.
| NUVB | TMDX | |
|---|---|---|
Market Cap | $1.71B | $2.81B |
Volume | 5,448,712 | 962,415 |
Sector | Health | Health |
52-Week High | $9.54 | $150.42 |
52-Week Low | $3.41 | $61.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $1.30B | $3.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics Group (TMDX) trades at $81.07, up 0.98% on the day, but remains in a technical downtrend with a bearish moving average signal. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying but also multiple legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 analyst target but faces near-term headwinds from earnings misses and legal overhangs. Key risks include execution pressure from heavy investments and ongoing legal scrutiny, while the core organ transplant technology business maintains a growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
